Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Alnylam Pharmaceuticals Inc (ALNY)  
$151.22 3.82 (2.59%) as of 4:30 Thu 5/16


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 123,030,000
Market Cap: 18.60(B)
Last Volume: 934,860 Avg Vol: 724,527
52 Week Range: $143.31 - $211.65
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  824
Guru Rank Value     : 0.5
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 45,264 76,855 102,504 247,093
Total Sell Value $6,835,665 $12,957,715 $17,713,340 $48,829,179
Total People Sold 6 7 8 9
Total Sell Transactions 10 12 18 35
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 746
  Page 17 of 30  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bonney Michael W Director   –       •      –    2015-05-12 4 B $112.16 $224,320 I/I 2,000 2,000 2.1     -
   Ausiello Dennis A Director   –       •      –    2015-04-21 4 AS $130.02 $1,061,613 D/D (8,165) 0     -
   Schimmel Paul Director   –       •      –    2015-04-21 4 AS $130.02 $1,300,200 D/D (10,000) 0     -
   Schimmel Paul Director   –       •      –    2015-04-21 4 OE $27.28 $286,850 D/D 10,000 10,000     -
   Ausiello Dennis A Director   –       •      –    2015-03-19 4 AS $120.00 $600,000 D/D (5,000) 8,165     -
   Schimmel Paul Director   –       •      –    2015-03-19 4 AS $120.00 $1,086,360 D/D (9,053) 0     -
   Schimmel Paul Director   –       •      –    2015-03-19 4 OE $27.28 $246,966 D/D 9,053 9,053     -
   Schimmel Paul Director   –       •      –    2015-03-17 4 AS $120.00 $113,640 D/D (947) 0     -
   Schimmel Paul Director   –       •      –    2015-03-17 4 OE $27.28 $25,834 D/D 947 947     -
   Vaishnaw Akshay EVP, R&D, CMO   •       –      –    2015-03-17 4 AS $115.29 $1,022,568 D/D (8,750) 0     -
   Vaishnaw Akshay EVP, R&D, CMO   •       –      –    2015-03-17 4 OE $7.10 $75,875 D/D 8,750 8,750     -
   Ausiello Dennis A Director   –       •      –    2015-03-05 4 AS $115.00 $81,190 D/D (706) 13,165     -
   Ausiello Dennis A Director   –       •      –    2015-03-05 4 OE $63.86 $45,085 D/D 706 13,871     -
   Fanucci Marsha Director   –       •      –    2015-02-25 4 AS $104.83 $1,057,953 D/D (10,000) 0     -
   Sanofi-Aventis 10% Owner   –       –       •   2015-01-29 4 B $95.00 $9,226,210 I/I 97,118 10,051,603 1.5     -
   Paul Steven M Director   –       •      –    2015-01-26 4 B $95.00 $95,000 D/D 1,000 1,000 2.39     -
   Maraganore John Chief Executive Officer   •       •      –    2015-01-26 4 B $95.00 $950,000 D/D 10,000 122,825 2.81     -
   Sanofi-Aventis 10% Owner   –       –       •   2015-01-26 4 B $95.00 $61,507,560 I/I 647,448 9,954,485 1.5     -
   Sanofi-Aventis 10% Owner   –       –       •   2015-01-22 4 B $9,317.00 $1,828,470,567 I/I 196,251 9,307,037 1.5     -
   Reid Laurence SVP, Chief Business Officer   •       –      –    2014-12-31 4 D $97.00 $271,794 D/D (2,802) 18,103     -
   Reid Laurence SVP, Chief Business Officer   •       –      –    2014-12-31 4 OE $15.99 $271,830 D/D 17,000 20,905     -
   Greene Barry E President and COO   •       –      –    2014-12-22 4 OE $13.12 $13,120 D/D 1,000 23,392     -
   Greene Barry E President and COO   •       –      –    2014-12-19 4 AS $100.00 $1,120,000 D/D (11,200) 22,392     -
   Vaishnaw Akshay EVP, Chief Medical Officer   •       –      –    2014-12-16 4 AS $91.47 $994,588 D/D (10,626) 0     -
   Vaishnaw Akshay EVP, Chief Medical Officer   •       –      –    2014-12-16 4 OE $7.10 $93,022 D/D 10,626 10,626     -
  746 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 17 of 30
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us